Posted by Defense World Staff on Feb 26th, 2026
AxoGen (NASDAQ:AXGN) reported fourth-quarter and full-year 2025 results that management said marked a “financial inflection point,” citing accelerating adoption of the company’s nerve repair algorithm, improved operating leverage,...
More of this article »